Curated News
By: NewsRamp Editorial Staff
November 07, 2026
ZEUS Trial: Ziltivekimab Lowers Inflammation But Not Cardiovascular Events
TLDR
- The ZEUS trial's neutral result opens a competitive edge for earlier-stage anti-inflammatory therapies targeting IL-6 or NLRP3.
- ZEUS randomized 6,376 high-risk adults to monthly ziltivekimab or placebo, finding no significant reduction in major cardiovascular events.
- Despite neutral results, ZEUS highlights the need to measure inflammation and manage heart-kidney health to improve future outcomes.
- Ziltivekimab cut CRP by 64% and IL-6 by 76% but did not reduce heart attacks or strokes in advanced disease.
Impact - Why it Matters
The ZEUS trial underscores that inflammation remains a validated but complex target for cardiovascular prevention. While ziltivekimab effectively reduced inflammatory markers, its failure to improve outcomes in advanced disease highlights the critical importance of timing and patient selection. For patients with ASCVD and chronic kidney disease—who face exceptionally high cardiovascular risk and limited treatment options—these results may feel discouraging. However, they refine our understanding: anti-inflammatory strategies may need to be deployed earlier in the disease process, before irreversible damage occurs. The findings also reinforce the need for routine inflammation screening and aggressive management of traditional risk factors. Ongoing research into upstream pathways like the NLRP3 inflammasome and earlier use of IL-6 inhibition offers hope for future therapies. In the meantime, adherence to proven preventive measures and comprehensive risk-factor control remains essential for reducing the burden of heart attack and stroke in this vulnerable population.
Summary
The phase III ZEUS trial, presented at the American Heart Association’s Scientific Sessions 2026 and simultaneously published in The New England Journal of Medicine, found that ziltivekimab—a monoclonal antibody that blocks interleukin-6—significantly lowered blood markers of inflammation but did not reduce the risk of major cardiovascular events in high-risk adults with atherosclerotic cardiovascular disease (ASCVD) and chronic kidney disease. The trial, funded by Novo Nordisk, enrolled more than 6,300 adults across 38 countries with confirmed ASCVD, clinically significant kidney disease, and elevated high-sensitivity C-reactive protein (hs-CRP). Participants received monthly subcutaneous injections of 15 mg ziltivekimab or placebo for a median of 29.1 months. Ziltivekimab reduced hs-CRP by 64% and IL-6 by 76% compared with placebo, yet the primary endpoint of heart attack, stroke, or cardiovascular death occurred in 561 participants in the ziltivekimab group versus 565 in the placebo group—a non-significant difference. Overall deaths were also similar (538 vs. 542). Serious infections were slightly more common with ziltivekimab (20% vs. 18%).
Lead author Paul M. Ridker, M.D., M.P.H., FAHA, of Harvard Medical School and Mass General Brigham, described the results as disappointing but cautioned against overinterpretation. He noted that prior research with the interleukin-1 inhibitor canakinumab and low-dose colchicine has shown that targeting inflammation can reduce cardiovascular risk, and that ZEUS participants had exceptionally advanced disease—more than 6% died during the trial, double the rate of other contemporary atherosclerosis studies. Ridker suggested the intervention may have been “too little, too late” for this population and emphasized the need to measure inflammation routinely. Future research will explore downstream IL-6 inhibition in earlier-stage disease and upstream targeting of the NLRP3 inflammasome. The American Heart Association’s 2026 guideline for cardiovascular-kidney-metabolic (CKM) syndrome and Life’s Essential 8 continue to stress comprehensive risk management, including healthy lifestyle and control of blood pressure, cholesterol, and blood sugar.
Source Statement
This curated news summary relied on content distributed by NewMediaWire. Read the original source here, ZEUS Trial: Ziltivekimab Lowers Inflammation But Not Cardiovascular Events
